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Abstract 
All acellular pertussis (aP) vaccines in use contain chemically inactivated pertussis toxin (PT). The finding that mice, naturally 
resistant to the effects of histamine, become sensitive upon injection of minute amounts of PT, led to the development of the test 
for residual PT known as the histamine sensitization assay (HSA). The HSA used by U.S.-licensed manufacturers is a limit test 
that shows that the residual bioactivity of PT in a single human dose of vaccine is below a threshold. Limit tests do not allow 
quantitative measurement. When the method is newly established at the point of use, three or more dilutions of pure PT are used 
to verify that mice injected with the vaccine came from a shipment that have sensitivity consistent with historical values. 
Sensitizability is expressed as an HSD50 (the dose that sensitizes 50% of a group of mice). However, once linearity of the dose 
response has been demonstrated, the assay may be simplified so as to include in each test only a single control group injected 
with PT. This assay simplification constitutes an example of the so-called “consistency approach.” A Japanese variant of the 
HSA uses a drop in body temperature as a nonlethal alternative index of PT-mediated sensitization and can provide a quantitative 
estimate of the residual PT activity of a vaccine. However, the advantage of a quantitative method is not obvious, because the 
amount of PT that is unsafe for humans is unknown. In addition, although the use of a nonlethal endpoint constitutes an important 
refinement, the need for a reference group in the test to obtain a quantitative estimate increases the number of animals required, 
relative to the number used in a simplified limit test. Moreover, the nonlethal endpoint might be adapted to the limit test format, 
and important steps have been taken in this regard. Finally, one option under early evaluation is the possibility of using the results 
from two in vitro assays, an enzymatic activity assay and a binding assay, to replace the HSA. 
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1. Background 
Pertussis (whooping cough) continues to be a worldwide public health concern even in countries with high 
vaccination coverage [1]. Public unease about the side effects of whole-cell pertussis (wP) vaccines prompted the 
development of acellular pertussis (aP) vaccines in the late 1970s and early 1980s. These vaccines contain up to five 
purified pertussis antigens and are less reactogenic than wP vaccines [2]. One of these antigens is pertussis toxin 
(PT), which in chemically detoxified form is included in all U.S.-licensed vaccines that contain an aP component. 
Thus, a test that measures the residual PT toxicity of chemically inactivated PT and the possible reversion of toxoid 
to toxin upon storage is important to ensure vaccine safety. 
PT is a typical AB toxin (one Active protomer plus a pentameric Binding oligomer). The B oligomer binds to 
various (but mostly unidentified) glycoconjugate molecules on the surface of a number of mammalian target cells. 
The enzymatic activity of PT resides in the A protomer. Once in the cell cytosol, A hydrolyzes cellular NAD and 
transfers the released ADP-ribose to a specific cysteine residue near the C-terminus of the α subunit of 
heterotrimeric G-proteins of the Gi family in mammalian cells. This modification alters a number of Gi protein-
coupled signaling pathways in a variety of cell types [3]. 
1.1. Toxicity of PT for humans 
Ideally, no toxic material should remain in vaccines; however, when the antigen itself is a toxin, the manufacturer 
is presented with the unique problem of achieving acceptably low levels of biological activity by detoxification 
while preserving a molecule with satisfactory levels of protective immunogenicity. Clinical studies in humans to 
quantitatively measure toxicity are obviously impossible to perform on ethical grounds. Additionally, detection of 
residual toxicity will be influenced by the assay method. 
Whole-cell pertussis vaccines, considered generally safe and effective [1], have been in use for many years (until 
1998 in the United States) and reportedly may contain up to 300 ng of active PT per dose [4]. Moreover, in a limited 
study of some therapeutic properties of PT, the intravenous injection of substantial quantities (up to 1 µg per kg of 
body weight) of active toxin into adult human volunteers failed to cause conspicuous adverse reactions [5]. 
Rather than basing it on known toxicity in humans, the acceptance criterion for residual PT in aP vaccines 
licensed in the United States was adopted on the basis of a set of principles that have become known as the 
“consistency approach” [6]. In this approach, product characteristics somewhat predictive of vaccine safety and 
efficacy are measured by analytical methods on vaccine batches after licensure. Similarity between these 
characteristics and those of batches demonstrated to be safe and effective in clinical trials is sought. This design 
limits the scope of a test result to its compatibility with a product of acceptable quality in the clinic. 
 
2. Use of the histamine sensitization activity of pertussis toxin in a toxicity test 
It was reported 62 years ago [7] that the treatment of mice with wP vaccine increased their sensitivity to the lethal 
effect of histamine by approximately 100-fold. Advances in the immunochemical characterization of Bordetella 
pertussis allowed investigators in the field to subsequently attribute this effect to PT. 
The numerous names that PT was given in the past (among others, leukocytosis-promoting factor, histamine-
sensitizing factor, and islet-activating protein) reflect the diverse cell types for which it may be noxious [8]. In 
principle, each of these and other effects, such as the growth in clumps of Chinese hamster ovary (CHO) cells 
cultured in the presence of the toxin, could be the basis for a test for residual activity; however, only one assay could 
detect residual PT in a matrix containing aluminum adjuvants and preservatives at an adequate level of sensitivity 
for aP vaccines: the histamine sensitization assay (HSA) [9]. Various other assays, such as the leukocytosis-
promoting assay (LPA) and the CHO-cell test [10], have been explored as alternatives to the HSA to detect residual 
active PT (Table 1). The LPA has shown poor reproducibility and large interlaboratory variation. Moreover, test 
sensitivity diminishes if the test sample must be injected using the intraperitoneal route instead of the intravenous 
route, such as when the presence of adjuvant precludes the use of intravenous injection. The CHO-cell test is useful 
for the determination of residual PT activity in pre-adsorbed bulk components and when the test vaccine in final 
bulk can be assayed at a higher dilution (as is the case with wP). However, the test is not suitable for testing for the 
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presence of residual active PT in final bulks of aP vaccine, because the aluminum salt used as an adjuvant or the 
presence of a preservative may cause CHO cell death at lower vaccine dilutions [9]. In addition, the correlation of 
this test with in vivo toxicity has been questioned [11]. 
Table 1. Some characteristics of three assays for active PT 
 CHO CELL ASSAY LEUKOCYTOSIS PROMOTION 
HISTAMINE 
SENSITIZATION 
DIFFICULTY + (in vitro) +++ (in vivo) + (in vivo) 
SENSITIVITY ≅ 135 pg/mL 
8-40 ng (i.v.) 
≅ 200 ng (i.p.) 
≅ 31 ng (HSD50) 
COST $ $$ $$$ 
SUITABILITY FOR FINAL 
BULK 
PT–unrelated toxicity of some 
vaccines for the cells 
Some adjuvants are toxic 
for the mouse via i.v.; i.p. 
route less sensitive 
YES 
 
The HSA is based on the principle that mice, which are usually resistant to the lethal effect of histamine, become 
sensitive upon injection of PT. The HSA is able to detect minute amounts of active residual PT, and it has therefore 
been chosen as the toxicity release test for aP vaccine. In this assay, groups of mice are injected concurrently with 
variable doses of pure active PT and the vaccine being tested. A few days later, animals are challenged with 
histamine [9]. Mice that received enough PT to be sensitized will go into hypovolemic shock. This is a condition 
where the heart is unable to supply enough blood to the body because of circulatory failure or inadequate blood 
volume [12]. Although most of the sensitized mice die of circulatory collapse within one hour, deaths due to 
histamine are recorded after 24 hours. The purpose of the dilution series of PT is to verify that the animals injected 
with the vaccine in a given day show sensitizability consistent with historical limits. Such sensitizability is defined 
in terms of an HSD50 (median histamine-sensitizing dose: the dose that sensitizes 50% of a group of mice to the 
lethal effects of histamine). The HSA can be used to validate detoxification procedures for PT, in terms of both 
residual toxicity and reversion, and to check other pertussis antigens for contamination with active PT. 
2.1. Toxicity testing of whole-cell pertussis vaccines 
The 2007 WHO recommendations for wP vaccine [13] describe a variation of the classical mouse weight gain 
test to assess vaccine toxicity, which was limited to record the weight and general health status of mice [14]. Blood 
is drawn on Day 7 post-injection from the mice injected with the vaccine being tested. An increase in the leukocyte 
count is considered to reflect the presence of PT in the vaccine. Additionally, the recommendations suggest the 
possibility of measuring PT in vaccines using the CHO cell assay [10] or the HSA test. 
Some laboratories have used the HSA to measure residual active PT in wP-containing vaccines relative to a 
reference vaccine to which a histamine-sensitizing unitage (HSU) has been assigned [15]. However, the European 
Pharmacopoeia [16] monograph for wP (0161, Pertussis Vaccine, Whole Cell Adsorbed) indicates that a 
semiquantitative CHO-cell assay should be used to assess the presence of active PT. Moreover, although the WHO 
Recommendations state that the levels of PT should be monitored during the detoxification processes, as well as 
when the methods used for detoxification are being validated and consistency of manufacturing is being established, 
they do not suggest limits [13]. 
3. Factors that affect the enhancement of histamine-mediated shock by PT in the mouse 
In the mouse, the treatment with PT alters or inhibits a basic physiological function that normally acts to protect 
against the toxic effects of many substances that kill the animal through hypovolemic or low-resistance shock. One 
of these substances is histamine. 
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Many factors influence the histamine-sensitizing activity of PT, including the strain, age, and gender of the mice 
used in the assay; the route of administration of the preparations; the amount of histamine used for the challenge; 
and a number of environmental factors that have not been well characterized. 
3.1. Mouse strain 
Several mouse strains with a Swiss-Webster ancestry are highly susceptible to histamine sensitization by PT. 
Their sensitivity tends to increase 50- to 100-fold upon PT injection. All Swiss mice come from two male and seven 
female albino mice imported into the United States by Dr. Clara Lynch of the Rockefeller Institute in 1926 [17]. 
These mice came from a noninbred stock in the laboratory of Dr. de Coulon, Centre Anticancereux Romand, 
Lausanne, Switzerland. On the other hand, a number of strains, both inbred and outbred, are poorly sensitized. 
3.1.1. Responsive strains 
Among the commercially available strains most responsive to sensitization by PT are those commonly referred to 
as ICR, CFW, and NIH, in current use in the United States. 
Hilltop’s Hla: (ICR)CVF Swiss mice originated at the Institute for Cancer Research (ICR) in Philadelphia. 
The Hauschka/ICR strain was initiated in 1948 from Swiss mice of Rockefeller origin. From the Institute of Cancer 
Research, the mice then went to Roswell Park Memorial Institute and then to Charles River Laboratories, Inc., in 
1959. In the 1970s, the mice were obtained by I.C.I. Americas, Inc., and rederived at Hilltop Lab Animals, Inc. In 
2002, the mice were rederived by cesarean section [18]. 
Crl:CFW(SW)BR resulted from the selective inbreeding by Dr. Leslie Webster using foundation animals from 
a large colony of Swiss mice maintained at the Rockefeller Institute. The strain went to Carworth from The 
Rockefeller Institute (now University). It was highly inbred when acquired by Carworth. Current mice come from a 
selected single pair derived in 1974 by cesarean section and progeny outbred from that point [19]. 
CR:NIH(S) mice originate from N:NIH(S) (known in the old literature as NIH-BS, NIH-BXS, NIH[SW], and 
NIH). This strain was derived in 1936 from 12 N:GP(S) mice with Swiss-Webster ancestry. The mice were 
maintained by multiple-branched inbreeding by brother-sister mating until a change to restricted random breeding in 
the mid-1960s. In 1973, N:NIH(S) mice were specific-pathogen-free derived and started being bred in a tightly 
controlled closed colony [20]. In 1986, mice started being bred by the Frederick National Cancer Research Facility 
at Fort Detrick, Maryland. 
Breeding procedures may seriously alter mouse sensitizability (Table 2). 
3.1.2. Nonresponsive strains 
Although outbred and inbred strains differ in susceptibility to histamine challenge after PT sensitization, only 
C3H/HeJ and CBA/J mice among 14 inbred strains were completely resistant to histamine sensitization at all doses 
tested using a histamine challenge dose as high as 100 mg/kg [21]. 
3.1.3. Genetics of histamine sensitization 
When administered in vivo, PT enhances vascular permeability, which is manifested by a concomitant increase in 
sensitivity to a variety of agents and treatments affecting the vascular bed. The marked differences between inbred 
mouse strains to the induction of histamine sensitization by pertussis vaccine implied that there was a genetic basis 
for this response [20]. Inbred strains of mice differ in susceptibility to vasoactive amine challenge after PT 
sensitization in that genetically susceptible strains die from hypotensive and hypovolemic shock, whereas resistant 
strains do not [12]. All the observations seemed to suggest that sensitization to histamine by PT in mice was 
regulated by a single dominant autosomal gene [22]. This was later confirmed [21]. Histamine sensitization by PT, 
as measured by hypersensitivity following vasoactive amine challenge, is genetically controlled by the B. pertussis-
induced histamine sensitization locus (Bphs). Bphs was mapped to the central region of mouse chromosome 6 [23], 
adjacent to genes belonging to the tumor necrosis factor (TNF) receptor superfamily [24]. Bphs has been identified 
as the histamine H1 receptor (Hrh1). It has been reported that the contribution of Bphs/Hrh1 to the overall genetic 
control of responsiveness to PT is limited to susceptibility to histamine hypersensitivity and enhancement of 
antigen-specific delayed-type hypersensitivity responses [25].  
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Table 2. Median histamine sensitizing doses (HSD50) of PT, ICR, and NIH mice of two sources 
STRAIN SUPPLIER HSD50 
ICR Taconic 280 nga 
ICR Hilltop 16 ngb 
NIH FCRF 23 ngc 
NIH HARLAN 225 ngd 
aGeometric Mean (GM) of 2 assays 
bGM of 5 assays 
cGM of 13 assays 
dGM of 12 assays 
3.2. Other factors 
Mouse age has also been suggested to affect the histamine-sensitizing effect of PT, although this factor seems to 
be less critical for some strains. Nevertheless, for example, the sensitivity of the CFW strain is thought to be more 
uniform among 5- to 7-week old mice than among younger animals [12]. It has been also reported that female mice 
are more sensitive to histamine sensitization than males, although the detection of this difference requires large 
numbers of animals [26,12]. The amount of histamine used for the challenge also affects the outcome of the assay. It 
has been reported that the number of deaths due to sensitization does not increase monotonically with the histamine 
challenge dose [27]. Therefore, the use of a fixed sensitizing dose of PT-containing material and variable histamine 
challenge doses was abandoned. 
To control for the effect of environmental factors not well understood, the use of a true randomization procedure 
to allocate the mice to treatment groups and for positioning cages on shelves is strongly recommended. 
4. HSA test designs for the testing of aP vaccines 
4.1. United States 
The standard HSA design used for aP vaccines licensed in the United States is as follows. Groups of 20 (4–5 
wks, 15–20 g, female) mice are injected intraperitoneally with 0.5 mL of the undiluted vaccine being tested, 
phosphate-buffered saline (PBS) containing 0.2% gelatin (diluent/negative control), or dilutions of PT (positive 
control). The PT dilutions are selected to cover a sensitizing range that will predictably include the HSD50. Five days 
after injection, all mice are challenged intraperitoneally with 1 mg of histamine base, as the monohydrated 
diphosphate, diluted in 0.5 mL of PBS. Within 1 hour, most of the sensitized mice will die of circulatory collapse 
and will be removed. Deaths are recorded at 24 hours. The assay is considered valid if there are no indications of 
departure from linearity of the log dose-probit line (p<0.01) and if the HSD50 is bracketed by the dilutions used and 
falls between 10 and 100 ng. In addition, no more than 10% of mice should die in the negative/diluent group. 
A vaccine is considered acceptable if one undiluted single human dose of 0.5 mL sensitizes no more than 10% of 
mice injected. If the vaccine fails to meet the criterion in a first test, to be recommended for release it should pass in 
two additional, consecutive and independent, tests. 
Results presented in Tables 2–6 were obtained in experiments performed using this basic design. 
4.1.1. Derivation of limits of mouse sensitizability by PT for assay validity 
The HSD50 of pure PT was estimated in multiple tests for three strains of mice reputed to be of suitable 
sensitizability to histamine (see 3.1.1 above). At least 10 valid assays per strain were used to estimate sensitizability 
limits. Linear models including all 36 results and dose, strain, and testing date as variables detected a significant 
difference in HSD50 among the three strains (Table 3). This result was confirmed by analysis of variance 
(p < 0.0025). CFW mice had a higher HSD50 than both ICR and NIH strains (Table 3), and the HSD50s of the ICR 
and NIH strains did not differ significantly from each other. 
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Table 3. Median histamine sensitizing doses (HSD50 in ng) for three strains of mice 
STRAIN n GMa HSD50 MEAN LOG S.D. LOG 
CFW 13 45.0 1.6523 0.1789 
ICR 11 26.7 1.4260 0.1436 
NIH 12 22.8 1.3582 0.2649 
aGeometric mean 
 
Because the three strains have been considered sensitizable, the upper validity limit was established using the 
HSD50 of the strain with the lowest sensitizability (CFW) and the lower validity limit was established using the 
HSD50 of the strain with the highest sensitizability (NIH): 
• HSD50 upper validity limit (antilog 97.5 percentile of HSD50 distribution for CFW strain): 10[1.6523 + 1.96(0.1789)] = 
100.7 ng, rounded to 100 ng 
• HSD50 lower validity limit (antilog 2.5 percentile of HSD50 distribution for NIH strain): 10[1.3582 - 1.96(0.2649)] = 6.9 
ng, rounded to 10 ng 
Alternative assay designs have been allowed if they are at least demonstrably equivalent in their capacity to 
detect residual active PT in aP vaccines. The setting of a lower validity limit by a manufacturer is optional, because 
the regulatory interest is to identify a shipment of low sensitizability, that is, one showing a higher-than-usual 
HSD50. 
 
Tables 4 and 5. Histamine sensitization of mice by aP from two manufacturers (A&B) spiked with 22 ng PT 
per 0.5 mL 
 Table 4 Table 5 
PT Conc.a Deaths @ 24h Injected mice  Vaccine
a Deaths @ 24h Injected mice 
125 ng 19/20  A 0/10 
25 ng 11/20  A + PT 8/10 
5 ng 0/20  B 0/10 
0 ng 0/20  B + PT 6/10 
aAssay HSD50 = 25.9 ng a0.5 mL per mouse 
 
4.1.2. Assay sensitivity 
The current HSA used by U.S.-licensed aP vaccine manufacturers is a limit test designed to demonstrate that the 
PT residual bioactivity in a single human dose of vaccine is below a defined threshold. Limit tests do not allow a 
quantitative measurement of the amount of residual active PT in the vaccine. Notwithstanding the successful use of 
this approach since at least 1991 in the United States, the international biologics community has expressed concern 
about the nonquantitative nature of the test. Moreover, despite the uncertainty of the amount of residual PT that 
detoxification procedures should achieve, a recent WHO informal consultation (November 9-13, 2009) on acellular 
pertussis vaccine recommended the use of the International Standard PT to calibrate the sensitivity of the assay 
system in IU of PT bioactivity (unpublished). For the sake of international harmonization, we at CBER have 
explored the possibility of estimating the amount of residual active PT that would cause the test outcome that has 
been considered as compatible with aP acceptance for almost 20 years. 
For example, the HSD10 (two mice sensitized from a group of 20) of PT in a shipment of mice with an HSD50 of 
exactly 100 ng (the minimal acceptable value: 10 mice sensitized from a group of 20) has a calculated value of 51.3 
ng (by probit analysis). For this modeling, three doses, equally spaced with a factor of five, were used. The 
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proportions of response to 500 ng and 20 ng were imputed to be 0.001 and 0.999, respectively (to prevent undefined 
probit values at the asymptotes while ensuring curve symmetry).  
 
Table 6. Proportion of mice of three strains sensitized to histamine by 100 ng PT 
Assay 
NIH CFW ICR 
HSD50 in ng # Dead at 100 ng HSD50 in ng # Dead at 100 ng HSD50 in ng # Dead at 100 ng 
1 23.5 18/20 6.29 15/20 23.2 16/20 
2 13.0 20/20 6.86 18/20 37.6 14/20 
3 17.4 19/20 5.26 20/20 16.2 19/20 
4 51.8 18/20 13.4 20/20 11.5 14/20 
5 16.2 20/20 10.1 15/20 7.13 17/20 
6 26.0 19/20     
7 21.8 20/20     
8 16.2 17/20     
9 7.3 20/20     
10 15.3 20/20     
 
On the other hand, to measure experimentally the quantity of active PT that must be present in a vaccine for it to 
fail the acceptance criterion, 3 mL of four vaccine lots from two different manufacturers were pooled separately to 
give a total of 12 mL of vaccine per manufacturer. Six milliliters were spiked with 2 µL of PT lot 1 @ 132 µg/mL to 
achieve a concentration of 22 ng of PT per 0.5 mL of vaccine. Twenty NIH mice were injected with the 
preparations, and the HSD50 of the PT used was estimated as per 4.1. The outcome of this experiment is shown in 
Tables 4 and 5. Results indicate that 22 ng of residual PT or even less in a vaccine matrix will make the vaccine fail 
the HSA. 
4.2. WHO guidelines 
The assay design description in the WHO guidelines for aP vaccines [9] indicates that groups of 10 to 20 mice of 
a set strain, gender, and age are allocated at random to three or more serial dilutions of pure PT and to one or more 
dilutions of the vaccine final bulk being tested. Another group, the negative control, is injected with diluent. After 
housing the mice for 4 or 5 days at random positions in the animal room, groups are challenged with histamine in 
the same order in which they were placed on the shelves. Deaths are recorded 24 hours after challenge. 
For the assay to be valid, mice injected with diluent should not show significant sensitization to histamine, and 
the HSD50 of PT for the strain used in the assay should be within an acceptable range. Experience has shown that a 
small percentage of mice (i.e., less than 5%) in the diluents control group may die following histamine challenge. 
Thus many laboratories will consider a test valid if there is no more than one death in this group. This clarification 
to the published guidelines was recommended at a recent WHO informal consultation on acellular pertussis vaccine 
(November 9-13, 2009, unpublished). On the other hand, a footnote in the current guidelines indicates that a strain is 
adequate for the test if the point estimate of HSD50 in each test is below 50 ng; however, it also indicates that 
variability of the estimate has to be taken into account when setting validity limits. The procedure described in the 
European Pharmacopoeia monograph (see Section 4.3) uses the point estimate only to define suitability when the 
assay is performed periodically for antigen concentrates. The HSD50 should be calculated using a suitable procedure, 
such as probit analysis, and the log dose-probit curve should not show significant departure from linearity 
(p < 0.01). The assay can be simplified by including a single positive control once linearity has been demonstrated 
over time. 
Acceptable residual activity is commonly expressed as the maximal proportion of mice that are sensitized to 
histamine by a dose (usually a single human dose) of the bulk. Activity should not exceed that of lots shown to be 
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safe in clinical studies. If the vaccine fails to meet the acceptance limit in a first stage, it should meet the criterion in 
two additional, consecutive and independent, assays to be deemed acceptable for marketing. 
If necessary, the amount of residual PT in vaccines being tested can be expressed as an HSD50. However, most 
currently licensed aP vaccines likely lack enough PT residual activity to allow meaningful calculation of an HSD50. 
The option of expressing residual activity in terms of an HSD50 may therefore be eliminated in future WHO 
documents. 
4.3. European pharmacopoeia 
The most recent edition of the European Pharmacopoeia (2010) includes monographs for Pertussis Vaccine 
(Acellular, Component, Adsorbed; Monograph 1356) and Pertussis Vaccine (Acellular, Co-purified, Adsorbed; 
Monograph 1595). The Purified Antigenic Fraction (Monograph 1595) or Purified Component (Monograph 1356) 
should be tested for residual pertussis toxin or its absence, respectively [16]. The test for residual pertussis toxin 
consists of the intraperitoneal injection of the fraction on test in a volume of no more than 0.5 mL.  Three groups of 
5 histamine-sensitive mice (18-26 g) each are administered the fraction diluted in PBS containing 0.2% gelatin, in a 
way to achieve a graded response. Diluent is injected into a fourth group. Five days afterward, mice are challenged 
intraperitoneally with 1 mg of histamine base in a volume of no more than 0.5 mL. Deaths are recorded in 24 hours. 
The result is expressed as the weight or volume of material that sensitizes 50% of the mice and is calculated by an 
algorithm such as probit analysis. The activity of the fraction should not exceed that of fractions used to prepare lots 
safe in the clinic (for Monograph 1595). The same test applies to the final bulk or final lot of vaccine.  
The test on antigenic fraction states that the sensitivity of the strain of mice should be verified at suitable intervals 
by showing that more than 50% of mice are sensitized with 50 ng of PT. None of the negative controls injected with 
diluent should die. Absence of reversion to toxicity is tested by means of the same assay design, but using vaccine 
(final bulk or final lot) that has been incubated for one month at 37ºC.  
For adsorbed pertussis vaccine (Acellular, Component, Monograph 1356), the test includes a single test vaccine 
group of mice. Each group will receive either (1) the equivalent of one human dose of the purified component 
administered intravenously or (2) the equivalent of twice the human dose administered intraperitoneally, in a volume 
of PBS–gelatin not to exceed 0.5 mL. If no animal dies in the test upon histamine challenge, the preparation 
complies with the specification. For final bulk or final lot of vaccine, a volume equivalent to twice the single human 
dose is injected intraperitoneally in at least five mice, and an equivalent dose of vaccine incubated for one month at 
37ºC is administered to a second group. All groups, including a negative control, are challenged intraperitoneally 
five days after injection with 2 mg of histamine base in a volume not exceeding 0.5 mL. No control mouse should 
die for the assay to be valid, and no test mouse should die for the assay to pass. The sensitivity of the strain of mice 
should be verified at suitable intervals by showing that more than 50% of mice are sensitized with 50 ng of PT. If 
one mouse dies in either test group, the test could be repeated. The assay passes if the total number of mice that die 
in all assays does not exceed 5%. All other test characteristics are similar to those already described.  
5. Changes to the HAS that impact the use of animals 
5.1. Inclusion of a PT standard in the lethal endpoint design 
In the U.S. test design, one or more dilutions of a pure PT preparation are included in every assay to verify the 
sensitizability of the shipment of mice used in each HSA test. The current material, U.S. PT control preparation, Lot 
1, consists of purified toxin at 132 µg/mL in phosphate buffer with 250 mM NaCl, pH 7.6, containing 50% glycerol. 
The preparation is stored at –20ºC conditions, under which it has remained stable after more than 13 years of use. 
The design of the basic U.S. assay as a nonquantitative test has been questioned on the grounds of classical 
bioassay principles that recommend the expression of bioactivity of a test sample in terms relative to that of a 
reference material to reduce assay variability [28]. Nevertheless, the International Conference on Harmonization 
[29] allows the use of either quantitative or limit tests for the control of impurities, such as residual active PT. 
In a collaborative study that was used as the basis for the adoption of the First International Standard of PT [30], 
the HSD50 estimate of the proposed standard was shown to vary between 39 and 1287 ng among the participants 
returning evaluable data. The study concluded that expressing PT activity in relative terms improves agreement 
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between laboratories about tenfold. However, a similar result might have been obtained by standardizing critical 
variables to ensure comparable assay sensitivity. For example, the design of the study allowed each laboratory to use 
the strain of mouse customarily employed. When the same mouse strain, or strains of similar sensitizability are used 
by two laboratories, variability may be substantially lower. For example, results submitted to the Center for 
Biologics Evaluation and Research (CBER) by a U.S.-licensed manufacturer in an 8-year period indicate that the 
HSD50 of the same PT control for the same mouse strain used during the entire period was 12.7 ng (10.9-14.7; 
geometric mean and 95% CI). Moreover, even the authors of the study acknowledged that higher variability on the 
estimate of residual PT in aP vaccines may not have clinical consequences as serious as those associated with wP, 
due to the important difference in residual activity between the two types of vaccine (see Sections 1.1 and 5.3). 
5.2. Use of a single PT positive control 
Substantial advancements in product characterization and process development, control and monitoring have led 
to the possibility of notable improvements in vaccine batch-to-batch consistency. This has allowed the 
popularization of a principle in use since at least the mid-1990s. Recently identified as the “consistency approach” 
[6], this testing philosophy is based on the concept that perfected analytical tools and the use of quality systems to 
guarantee consistency in both production and testing methods help a manufacturer offer assurances that any batch 
manufactured post-licensure possesses characteristics similar to those batches already shown to be safe and effective 
in the target population. In this approach, test designs, including those using animals, are critically examined in the 
light of their ability, as a set, to predict safety and efficacy in the target population. Therefore, the extensive 
adoption of the framework may lead to a considerable reduction, refinement, or even replacement of the use of 
animals for vaccine testing. 
A reduction alternative based on the consistency approach is the substitution of a multidose test with a single-
dose test once it has been established through repeated testing that good quality product is being consistently 
produced and that required animal testing reliably displays desirable characteristics (e.g., linearity of the response). 
This reduction has already been adopted for the potency testing of diphtheria and tetanus toxoids [31]. 
Studies were performed in our laboratory to generate data in support of a reduction in the number of mice used in 
the HSA test by using a single positive control group rather than the three or more groups of mice originally used to 
calculate the HSD50. Acceptance of this modification required experiments designed to verify that a prespecified 
dose of PT, at or below 100 ng, would consistently sensitize more than 50% of the mice injected. For this purpose, 
groups of mice of the three strains found sensitizable were injected with 100 ng of pure PT in five to ten tests 
performed according to the routine method, which includes a three-dose PT titration curve. This dose was found 
adequate to consistently sensitize more than 50% of the mice injected (Table 6). 
The number of mice employed for HSA testing of U.S.-licensed vaccines containing an aP component has been 
reduced by persuading one manufacturer to switch to the use of a single positive control group for assay validity 
assessment on the basis of the above information and its own studies. 
Three manufacturers of aP vaccines are licensed in the United States. One manufacturer has used a single-control 
assay since licensing of their first combination. In a 10-year period, 200 bulk lots of this vaccine were released for 
distribution, involving the sensitization of 1265 mice in control groups of the HSA. Another manufacturer had used 
an HSD50 control since the licensing of their first combination containing an aP component. In a period of almost 9 
years, around 97 bulk lots of this vaccine were released for distribution, requiring the sensitization of 3171 mice in 
control groups of the HSA. The latter manufacturer was persuaded to use a single positive control group for assay 
validity assessment on the basis of their testing history, our experimental results, and their own data analysis. 
Approval of the use of a single control group in HSAs was granted to this manufacturer in 2008. As part of the 
approval, the manufacturer committed to verify the sensitizability of the mouse strain at least three times per year 
using the original multidose test for the positive control. Since approval of the simplified procedure, 14 to 20 mice 
are sensitized in the positive control group per test (vs. a median of 50 per test before the modification). 
5.3. Quantitative HSA with a nonlethal endpoint 
As part of the development of copurified aP vaccines in Japan, the need for a method to replace the traditional 
HSA was identified, because the existing procedure involving a lethal challenge was found to be not sensitive 
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enough to detect an expected tenfold reduction in residual PT activity, relative to that contained in wP vaccines [32]. 
An HSA developed by Ishida et al. [33] used change in mouse rectal temperature as the response, instead of death, 
following histamine challenge. This test was included in the Japanese Minimum Requirements of Biological 
Products in 1981. In this test, groups of ten mice each were intraperitoneally injected with 0.5 mL of dilutions of a 
reference wP vaccine (to which an activity in HSU/mL had been assigned) and the aP vaccine being tested. The 
mice were intraperitoneally challenged 4 days afterward with 4 mg of histamine dihydrochloride in 0.5 mL of saline. 
Rectal temperature was recorded 30 minutes after challenge using a thermocouple attached to an electronic 
recording device, and activity was calculated using a parallel line assay with temperature as the dependent variable 
and log dose as the independent variable. Lack of reversion to toxicity was assessed as above using vaccine that had 
been incubated for one month at 37ºC. Copurified aP Japanese vaccines passed the test if their PT activity did not 
exceed 0.8 HSU/mL. Clinical studies in the mid-1980s revealed that some Japanese aP vaccines were prone to 
reversion to PT toxicity over time. To prevent this from happening, the limit of acceptance was revised to no more 
than 0.4 HSU/mL in 1991; it remains as such to date. Changes in manufacturing that were made to ensure the 
meeting of this specification had a noticeable impact on the residual PT activity of pertussis concentrates used for 
further manufacturing of aP vaccines licensed in the United States for toddler use also in 1991. 
A study of the agreement of testing outcomes for non-Japanese aP vaccines, using the Japanese and other assay 
designs (U.S., EU WHO), was recently published [34]. The rationale for the investigation was the claimed 
superiority of the measurement of body temperature instead of lethality as an index of histamine sensitization for the 
detection of lower amounts of active PT in aP vaccines. However, results were rather uninformative, because many 
current products give a negative response in the lethal HSA models [35]. In addition, the clinical superiority of a 
quantitative method over a limit test is not immediately evident. Although, in principle, the results of such a test 
could be used to establish a proportional relationship with adverse events in the target population, meaningful 
studies to this effect are very difficult, if at all possible, to implement. Nevertheless, a feasible advantage of a 
quantitative estimation of residual aP is that such a result may allow more precise tracking and trending of data to 
maintain product consistency, because it provides a result in an interval scale. 
A simplification of the HSA nonlethal refinement has recently been described. In it, an infrared thermometer is 
used to measure a drop in dermal temperature following the histamine challenge, instead of the change in rectal 
temperature [35,36]. 
5.4. Use of a nonlethal endpoint in a limit HSA 
The possibility of using a nonlethal endpoint such as a drop in body temperature may constitute an important 
refinement, even though at this time some deaths still occur before mice can be humanely sacrificed. Moreover, the 
need for a reference group in the test to obtain a quantitative estimate of residual PT activity increases the number of 
animals required relative to the number used in a simplified limit test. 
A potential way to circumvent the latter conundrum is to adapt the nonlethal endpoint to the limit test format. 
This has been reported by a group at the Danish Staten Seruminstitut (Jensen, personal communication). In the 
procedure that they have validated, the researchers inject each of four groups of C57BL mice intraperitoneally with 
either two single human doses of aP-containing test vaccine, the same dose of a control aP, or the control aP spiked 
with 50 ng of PT and PBS-gelatin buffer. Five days after sensitization, mice are challenged with 1.2 mg of 
histamine, and the drop in dermal temperature is recorded 30 minutes after challenge. The assay is valid if the drop 
in temperature (signal) following histamine challenge in mice injected with the aP control does not differ 
significantly from that of mice injected with buffer and if signal due to injection with spiked aP is significantly 
different from that due to nonspiked aP. The vaccine passes the test if the signal due to its injection is less than or 
equal to that due to the injection of the aP control vaccine. The method has been shown to have greater sensitivity 
than the lethal test, being able to detect as low as 6.25 ng of active PT in a human dose of Danish aP vaccine.  
5.5. Potential replacement of the HSA to detect residual PT activity in aP vaccines 
The majority of the toxic effects of PT have been attributed to the A-catalyzed ADP-ribosylation of the α-
subunits of signal-transducing guanine-nucleotide-binding proteins. This led to the proposal of using an assay to 
measure this enzymatic reaction as an in vitro replacement for the HSA. An assay based on the chromatographic 
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separation and measurement of an ADP-ribosylated fluorescent substrate [37] was standardized [38,39]. However, 
PT has two functionally distinct domains, and the B-oligomer not only mediates the entry of A into the host cell, but 
possesses activities on its own [3]. By limiting a test for residual PT activity to measuring the ADP-ribosylating 
activity present in the aP vaccine, toxic activities due to the B oligomer may be overlooked. Nevertheless, the 
clinical risk of this limitation is low, because the B oligomer lectin-like activities require substantially higher protein 
concentrations for their expression. However, another important disadvantage of such an approach is that vaccines 
that cannot impair cell function might still show residual enzymatic activity. This is due to the fact that PT 
detoxification is a complex process that involves modification of multiple protein sites. For example, it has been 
proposed that formaldehyde, used for PT detoxification, although reactive with several amino acids, reacts 
preferentially with the ε amino group of lysine [40], and there are no lysine residues in the A protomer, making it 
potentially more difficult to detoxify than the B oligomer. Because of these concerns, an enzyme-linked 
immunosorbent assay (ELISA) system to monitor the modification of the B oligomer by detoxifying agents was 
developed as a potential complement of the enzymatic assay [41]. The assay is reported to be able to detect the loss, 
upon detoxification, of the ability of PT to bind to defined oligosaccharides or glycoproteins in the presence of other 
antigen components of aP in combination vaccines.  
Recently, Yuen et al. proposed a combination of results of these two in vitro assays as a replacement for the HSA 
[39]. Such a suggestion is premature. The authors of the initiative made a strenuous effort to find a correlation 
between the nonlethal version of the HSA and a combination of both in vitro outcomes. Even then, a common 
correlation could not be found for all types of vaccines studied. Additionally, it is important to recall that correlation 
between two methods is not equivalent to agreement between pairs of results [42]. For the two versions of the HSA, 
a common acceptance limit for all vaccines has been established in at least Japan (nonlethal outcome) and the 
United States (lethal outcome). In this context, the authors of the study chose to limit the comparison of the in vitro 
combined index to the HSA outcome obtained using the Japanese design, which has never been directly compared to 
the lethal endpoint design or anchored to clinical behavior of aP vaccines. There is at this point no indication on how 
an acceptance limit could be set for residual PT activity using the dual in vitro assay proposed. 
6. Conclusions 
Mice have provided an invaluable service for the release of pertussis vaccines with improved public 
acceptability. The HSA in its two designs (using a lethal and a nonlethal endpoint to measure sensitization) has 
served well to ensure the release of aP vaccines with acceptable residual PT activity. Encouraging progress has 
occurred in the path to reducing and refining the use of mice for the toxicity testing of this type of vaccine. 
However, substantial advancement could occur if the test were critically examined in the context of the consistency 
approach and if harmonization were sought in good faith on a global scale. The HSA could become a limit test that 
uses a single PT positive control and a nonlethal endpoint to indicate sensitization to histamine. The test can be 
humanely stopped before hypovolemic-hypotensive shock progresses to death. If tight control of PT inactivation is 
ensured in-process by an adequate in vitro method, the quantitative in vivo measurement of residual PT activity may 
not be warranted in light of the impossibility of establishing with numerical certainty the amount of PT that is 
clinically hazardous. Despite their limitations, steps towards the replacement of an in vivo toxicity test for aP 
vaccines with an in vitro test for residual PT activity in final bulks of aP vaccines are heartening. The chosen 
method does not need to be unduly complex but need only provide assurance that residual PT activity in all types of 
aP vaccine is below a level consistent with lots shown to be safe in the clinic. More research is required to reach 
universal consensus on such a level. 
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